Key Highlights
- UnitedHealth Group (NYSE:UNH) shares gained 4.24% to USD 344.51 on November 20, 2026.
- TD Cowen upgraded to Buy from Hold with a USD 455 target.
- The stock slid 17% to 20% in five days on CMS's proposed CRUSH rule.
- The CRUSH comment period runs to January 19, 2027.
Upgrade After a Regulatory Sell-Off
UnitedHealth Group (NYSE:UNH) gained 4.24% to USD 344.51 on November 20, 2026, on trading Volume of 6.27 million shares, after TD Cowen upgraded the stock to Buy from Hold, raised its target to USD 455 from USD 402 and named it a 2027 Best Idea. The firm cited a credible path to mid-to-high-teens EPS growth through 2028, driven by Optum Health recovery and improving commercial and Medicaid margins. The rebound follows a roughly 17% to 20% five-day slide on the proposed CRUSH rule from CMS, which would extrapolate Medicare Advantage audit findings across whole contracts back to payment year 2018, an industry cost of about USD 9 billion a year, and renewed Medicare for All proposals. The stock closed at USD 330.48 on November 19, down 5.55%, its third straight losing session. UnitedHealth is the largest US health insurer and also runs Optum, which provides care delivery, pharmacy services and data analytics, so changes to Medicare Advantage payment rules touch both its insurance and services segments.
Why the Rule Matters and What Analysts Say
Medicare Advantage plans are paid by the government based on patient risk scores. Audits check whether those scores were justified. Extrapolating audit findings means a small sample of errors could be applied to a whole contract, which would force repayments across many years. Bernstein, Mizuho and others have argued the sell-off was overdone, but the comment period runs to January 19, 2027, so regulatory uncertainty persists. Supporters argue that faster-than-expected Medicare Advantage and Optum Health recovery supports targets up to USD 531, with three guidance raises to at least USD 20.50 of EPS and a Long-term Growth target of 13% to 16%. The market Capitalization is USD 308.68 billion and the trailing price to Earnings ratio is 19.66.
Risks: Valuation, Optum and Policy
Skeptics argue that valuation already prices in much of the expected 2027 to 2028 earnings rebound. Baird holds a Neutral rating with a USD 427 target on that logic. The Optum turnaround is unproven, and recovery depends on cost discipline, not enrollment growth, which is deliberately shrinking. Regulatory, Justice Department and policy risks could pressure the multiple, and the final CRUSH rule could differ from the proposal. Trading volume was below normal, with relative volume of 0.82, so the bounce was not backed by unusual buying. Trailing diluted EPS growth of negative 8.56% shows that earnings have fallen over the past year. Watch the comment period, medical cost trends and 2027 guidance credibility. Because the proposal is open for public comment, insurers, hospitals and lawmakers can all weigh in, and CMS may soften, delay or finalize the rule as written. Each of those outcomes would change how the market values Medicare Advantage earnings, so headlines on the topic are likely to keep moving the shares.
Where Things Stand
UnitedHealth Group (NYSE:UNH) gained because TD Cowen upgraded it to Buy with a USD 455 target after a roughly 17% to 20% five-day slide, and because buyers argued the CRUSH rule sell-off was overdone. The rule is only proposed, but the comment period runs to January 19, 2027. On the flip side, valuation already prices a rebound, Optum is unproven and policy risk remains. The stock is US-listed, so this reflects Friday's US session.






Please wait processing your request...